Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Intra-Cellular Form 4	Therapies, Inc.										
July 02, 2014	,										
FORM	$ 4 _{\text{UNITED}}$	статес	SECU	DITIES A	ND FY(THANCE	COMMISSION	т	PPROVAL		
	UNITED	SIAIES		shington,				Number:	3235-0287		
Check thi if no long subject to Section 10	er STATEN	AENT O	OF CHANGES IN BENEFICIAL O SECURITIES				WNERSHIP OF	Estimated			
Form 4 or Form 5 obligation may conti <i>See</i> Instru 1(b).	Filed pur Section 17(a) of the	Public U	l6(a) of th	e Securit ling Corr	pany Act	nge Act of 1934, of 1935 or Sectio 940	burden ho response on			
(Print or Type R	esponses)										
1. Name and Address of Reporting Person <u>*</u> Mates Sharon			2. Issuer Name and Ticker or Trading Symbol			-	5. Relationship of Reporting Person(s) to Issuer				
			Intra-Cellular Therapies, Inc. [IT			nc. [ITCI]	(Che	ck all applicab	k all applicable)		
(Last)	(First) (I	Middle)		of Earliest Tr	ansaction		X Director	10	7 Owner		
	-CELLULAR S, INC., 3960 Y		06/30/2	Day/Year) 2014			X Officer (giv below)		% Owner ner (specify CEO		
(Street)			4. If Amendment, Date Original				6. Individual or Joint/Group Filing(Check				
NEW YORK	K, NY 10032		Filed(Mc	onth/Day/Year)		Applicable Line) _X_ Form filed by Form filed by Person	One Reporting F More than One R			
(City)	(State)	(Zip)	Tab	le I - Non-D	erivative S	Securities A	cquired, Disposed o	of, or Beneficia	ally Owned		
	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transaction Code (Instr. 8)	Disposed of (Instr. 3, 4	A) or of (D)	Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V		or (D) Price	Transaction(s) (Instr. 3 and 4)				
Domindari Don	ort on a separate line	for each a	ass of soo				ar indiractly				
Kennider. Kep				unites ocher	Person inform require	ns who res ation cont ed to respo ys a currer	spond to the colle- ained in this form and unless the for ntly valid OMB co	are not rm	SEC 1474 (9-02)		
	Tab			curities Acquis, warrants			Beneficially Owned securities)	l			
1. Title of 2.	3. Trans	action Date	3A. Dee	emed	4.	5. Number	of 6. Date Exerc	cisable and	7. Title and Amount of		

Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative

Underlying Securities

Expiration Date

Edgar Filing: Intra-Cellular Therapies, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	3) A I (Securities (Mont Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day	(Year)	(Instr. 3 and 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 16.86	06/30/2014		А		200,000		<u>(1)</u>	06/30/2024	Common Stock	200,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Mates Sharon C/O INTRA-CELLULAR THERAPIES, INC. 3960 BROADWAY NEW YORK, NY 10032	Х		Chairman, President & CEO				
Signatures							
/s/ Lawrence J. Hineline, Attorney-in-fact	07/02/2014	1					
**Signature of Reporting Person	Date						
Evaluation of Decanonace							

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests as to one third of the shares on December 13, 2014, one third of the shares on December 13, 2015 and one third of the shares on December 13, 2016.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.